Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | ROR1 | Q01973 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840388 | 0.81 | MKNK1 (0.49) | MKNK1KLK7DYRK1AEGLN2 | |
| SCHEMBL22369939 | 0.79 | MKNK1 (0.46) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL16704334 | 0.79 | MKNK1 (0.46) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL588504 | 0.76 | MKNK1 (0.44) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL10207631 | 0.76 | MKNK1 (0.44) | MKNK1DYRK1ACSF1RROR1ABL1 | |
| SCHEMBL24496139 | 0.75 | MKNK1 (0.43) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL16201030 | 0.73 | MKNK1 (0.41) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL29890013 | 0.73 | MKNK1 (0.41) | MKNK1KLK7DYRK1ACSF1RROR1 | |
| SCHEMBL477032 | 0.71 | MKNK1 (0.53) | MKNK1KLK7DYRK1AEGLN2SSTR4 | |
| SCHEMBL22510132 | 0.71 | MKNK1 (0.53) | MKNK1KLK7DYRK1AEGLN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-111004240-B | Synthetic method of ponatinib intermediate 3-ethynylimidazo [1,2-b ] pyridazine | 山东铂源药业有限公司 | 2020-12-01 | — | — | CN | claimed |
| CN-111004240-A | Synthetic method of ponatinib intermediate 3-ethynylimidazo [1,2-b ] pyridazine | 山东铂源药业有限公司 | 2020-04-14 | — | — | CN | claimed |
| US-9988389-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2018-06-05 | — | — | US | claimed |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2018-02-15 | — | — | US | claimed |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | MYLAN API US LLC | 2016-12-15 | — | — | US | claimed |
| WO-2016201203-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-12-15 | — | — | WO | claimed |
| US-9493473-B2 | Processes for making ponatinib and intermediates thereof | APICORE US LLC (US) | 2016-11-15 | — | — | US | claimed |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2016-04-21 | — | — | US | claimed |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| EP-1973545-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | RIPK1, RIPK2, RIPK4 | MKNK1 20/4885KLK7 2171/4885DYRK1A 2266/4885 |
| US-20180044345-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MKNK1 639/4885KLK7 4121/4885DYRK1A 714/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | MKNK1 4046/4885KLK7 2863/4885DYRK1A 4673/4885 |
| US-20160362411-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MKNK1 639/4885KLK7 4121/4885DYRK1A 714/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | MKNK1 747/4885KLK7 4388/4885DYRK1A 178/4885 |
| US-20160108053-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MKNK1 428/4885KLK7 4087/4885DYRK1A 523/4885 |
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | MKNK1 428/4885KLK7 4087/4885DYRK1A 523/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | MKNK1 4046/4885KLK7 2863/4885DYRK1A 4673/4885 |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | ABL1, BCR, LTK | MKNK1 315/4885KLK7 3656/4885DYRK1A 257/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | MKNK1 66/4885KLK7 1554/4885DYRK1A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.